Obese Patients (BMI ≥ 30 kg/m²)Si-OBANCT07020741
Stable Isotopes- Adults With Obesity
A study testing Indispensable Amino Acid Oxidation and Stable Isotope Oral Glucose Tolerance Test in people with Obese Patients (BMI ≥ 30 kg/m²) and Glucose Metabolism, run by University of Illinois at Urbana-Champaign at 1 site in United States.
Trial summary
In a crossover design, 8 participants will receive caloric drinks containing stable isotopes. In one arm of the study, participants will consume 6 hourly drinks containing two stable isotopes. Repeated blood, breath, urine, and muscle biopsies will be taken. Read more about this study
- Who is it for?
- Ages 19 to 59 yearsHealthy volunteers can take part
- Conditions the study is for
- Obese Patients (BMI ≥ 30 kg/m²), Glucose Metabolism, Protein Metabolism
- What is being tested?
- Indispensable Amino Acid Oxidation and Stable Isotope Oral Glucose Tolerance Test
- Type of treatment
- Pill or oral medicine, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 8 participants
- Where
- 1 siteUnited States
- Study dates
- 12 Sep 2025to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 59 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- ages 19-59
- Obese >/= 30 kg/m^2 and >/= 102 cm for males and >/= 88 cm for females
- Godin Leisure-time or exercise questionnaire <14 units
Who cannot join
- Pregnant or become pregnant
- Any known food allergies
- Smoker
- Are physically active
- Have any known metabolic diseases
- Have been weight unstable within the last 6 months (lost or gained >10% of body mass)
- Non eumenorrheic or on a hormonal birth control
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Freer Hall - University of Illinois
Urbana, Illinois, 61801
Nicholas Burd (Associate Professor), PhD, 2172440970, naburd@illinois.edu
Gena L Irwin Research Assistant, M.S, 3608883281, genai2@illinois.edu
About this study
Official title: Assessing Metabolic Health With Stable Isotope Tracer Techniques in Adults With Obesity
In a crossover design, 8 participants will receive caloric drinks containing stable isotopes. In one arm of the study, participants will consume 6 hourly drinks containing two stable isotopes. Repeated blood, breath, urine, and muscle biopsies will be taken. In the second arm, participants will consume 1 drink containing 75g glucose, labeled with two stable isotopes of glucose. Periodic blood and breath will be taken over three hours.
Read the detailed description
- Enrollment, Informed Consent, and Screening Questionnaires (Virtual): Prior to study enrollment, participants will be asked to read a digital copy of an informed consent document provided using the e-Consent framework through the Research Electronic Data Capture (REDCap) system. Should participants have any questions about the study after reading the document, they will be encouraged to contact the research team prior to providing informed consent. Upon provision of informed consent, participants will receive an email with questionnaires designed to assess eligibility for the study through REDCap. Specifically, participants will be asked to complete a health and medical history questionnaire, physical activity readiness questionnaire (PARQ), International Physical Activity Questionnaire Long Form (IPAQ), and Godin-Shephard Leisure-Time Physical Activity Questionnaire (LTPAQ). Information from the medical history questionnaire, PARQ, and LTPAQ will be used to assess exclusion criteria and the IPAQ be used to assess baseline habitual activity level. Upon completion of these questionnaires, the research team will review responses and determine eligibility. Should Participants be eligible, researchers will work with the participant to schedule subsequent visits
- Preliminary Testing (Visit 1): Participants will arrive for the preliminary testing session after an overnight fast.
Urine samples: 30mL of urine at time points -30 min, 0 min, 240 min, 300 min, and 360 min. Briefly, participants will be provided with a urine collection cup, alcohol wipes, and gloves and asked to fill the cup about 3/4 of they way.
Blood Collection: ~88 mL will be collected during the trial.
Breath Collection: At -30 minutes, 0 minutes, 120 minutes, 240 minutes, 300 minutes, 360 minutes, we will measure the air exhaled. To do this, participants breathe normally through a hose. Immediately after, they will exhale into a separate mouthpiece attached to a plastic bag.
Muscle Collection: A total of 2 muscle biopsies will be collected during the trial. The biopsy procedure involves removal of a small piece of muscle tissue using a sterile hollow needle (Bergström needle) and will be performed by Dr. Nicholas Burd under the auspices of Dr. Jared Willard, MD. Participants will rest on a bed and the area for the biopsy will be shaved, if required. Subsequently, the area will be sterilized using 4% chlorhexidine gluconate before 5 mL of local anesthetic (2% Xylocaine with 1:100,000 epinephrine) is injected subcutaneously with special care to avoid infiltrating the muscle. Once the anesthetic is active, a small incision will be made in the skin in order to create an opening through which to put the biopsy needle for tissue collection. Dr. Burd will quickly cut of a small piece of muscle. the subjects may feel a sensation of deep pressure in their leg. A sterile disposable drape will be placed under the participant's thigh and sterile gloves will be used for all biopsy procedures.
After the biopsy is completed, a trained research team member will apply pressure with sterile gauze until the bleeding stops (at least 15 minutes). Subsequently, the incision site will be closed using butterfly stitches (Steri-strips) following by application of a bandage. An elastic pressure wrap will be applied on top of the bandage in order to minimize the chance of bruising. Participants will then be instructed to leave the butterfly stitches and the pressure wrap on the wound for 96 and 24 hrs, respectively.
The participant will be provided with a "biopsy care kit" (described in section 10.1/Biopsy care kit) in order to properly care for the incision after leaving the laboratory. A member of the research team will contact the participants in the day following the trial to check on the healing process.
After blood, breath, and muscle samples of time 0, participants will drink the first of a series of drinks containing [13C]phenylalanine and [2H5]phenylalanine at a ratio of 1:10 with a 1:10 ratio of total tracer to tracee (naturally occurring phenylalanine) The first drink will be primed with NaH13CO2 (0.176 mg/kg) in addition to [13C]phenylalanine and [2H5]phenylalanine mixture. Drinks will be consumed every 30 minutes for the duration of the procedure.
These drink will also contain 1.2x estimated RMR calories (divided into 12 drinks)
VCo2: Carbon dioxide production (VCO2) will be determined from expired air sampled by open circuit spirometry using an on-line, computer-based acquisition system. Participants will breathe through a one-way, high velocity non-rebreathing valve. The volume of expired air is measured by a gas flow meter. The carbon dioxide concentrations of expired air are assessed by a carbon dioxide analyser. Analog data from the gas analyser and flow meter is digitized and sent to an IBM compatible PC for calculation of VCO2 converted to Standard Temperature and Pressure Dry. Immediately after VCO2 analysis is performed (5 min), subjects are asked to exhale into a separate mouthpiece attached to a plastic bag. This particular breath sample is stored in a sterile vacutainer for future analysis of stable isotope tracer enrichment in the breath. The measurement of carbon dioxide production (VCO2) and the measurement of tracer enrichment in the breath allow us to assess how much of the protein is used for energy, rather than for building skeletal muscle proteins. Subjects are not expected to experience any discomfort from this procedure, nor will it influence their physical well-being.
(Visit 4) Stable Isotope OGTT: within 7 days after the first trail participants will be asked to return to the lab for a second procedure.
Blood Collection: Blood collection procedures will be exactly as described above. There will be a total of 9 blood collections (time -10, 10, 20, 30, 60. 90, 120, 150, 180) minutes Breath Collection: Breath collection procedures will be exactly as described above. There will be a total of 9 breath collections (-10, 10, 20, 30, 60, 90, 120, 150, 180) minutes After the blood and breath collection for time -10 minutes, participants will be asked to consume a 75 g Glucose Drink dissolved in 250 ml of water enriched with [6,6_2H2]glucose and [13C6]glucose. As stated above, blood and breath samples will be taken periodically over the next 3 hours.
- Being tested
- Indispensable Amino Acid Oxidation, Stable Isotope Oral Glucose Tolerance Test
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Indispensable Amino Acid OxidationProcedure or surgery
Also called IAAO
Participants will ingest six hourly meals designed to provide 50% of the daily intake of 1.1 g·kgLBM. Additional energy (1.5x daily resting metabolic rate), carbohydrate (55%), and fat (35%) will be provided in beverages and protein-free cookies (for palatability). The first drink will contain priming doses of NaH13CO2 (0.176 mg·kg-1), [13C]phenylalanine (1.86 mg·kg-1), [2H5]phenylalanine (0.34 mg·kg-1) with all subsequent drinks containing 1.2 mg·kg-1 [13C]phenylalanine and 0.51 mg·kg-1 [2H5]phenylalanine.
Stable Isotope Oral Glucose Tolerance TestProcedure or surgery
Also called Si OGTT
Participants will consume a 75g glucose drink dissolved in 250 ml of water enriched with [6,6_2H2]glucose and [13C6]glucose.
| Study group | Role | What they receive |
|---|---|---|
| IAAO | Experimental | Participants will ingest a series of 6 hourly beverages containing 50% of the daily intake of 1.1g/kg/day Receives: Procedure: Indispensable Amino Acid Oxidation |
| SIOGTT | Experimental | Participants will consume one 75g glucose drink dissolved in 250 ml of water. Receives: Procedure: Stable Isotope Oral Glucose Tolerance Test |
What is being measured
The primary outcome is the main question the study is designed to answer.
Define obesity-related whole body protein efficiency based of the IAAO method
Amino Acid Oxidation of phenylalanine will be measured using the IAAO method by periodic ingestion of amino acid mixture. Trials will start at ~7:00 am (-30 minutes) with a total duration of 6.5 hours (390 minutes) Measurements of breath (-30, 0, 120, 240, 270, 300, 330 and 360 minutes), Urine (-30, 0, 240, 300, and 360 minutes), muscle biopsy (-30 and 360 minutes) and blood (-30, 0, 30, 60, 90,120, 180, 240, 300, and 360 minutes) will be used to determine the whole body efficiency of protein in obese populations.
Measured: 0 - 6 hours observational period ingesting six hourly meals, within 1 week of preliminary testing. Baseline measures taken at --30 minutes.
Assessment of oral glucose tolerance based on a dual tracer technique
Measure glucose kinetics via [13C] and D5 Glucose over 3 hours to determine glucose tolerance. Trials will start at ~7:00 am (-10 minutes) and last ~ 3 hours. (190 minutes)
Measured: 0- 3 hour observational period. Within 1 week of the prospective arm. Baseline taken at -30 minutes.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jun 2025
- Study start12 Sep 2025
- Primary completion30 Aug 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Obese Patients (BMI ≥ 30 kg/m²)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- The study will employ a crossover model where they will complete 2 of 2 conditions, in a randomized order.
- Masking
- None (open label)
- Enrolment
- 8 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Illinois at Urbana-Champaign
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07020741
- Sponsor's protocol ID
- IRB25-0166
- Other IDs
- RB25064
- Acronym
- Si-OBA
- Status last verified
- Jun 2025
- First submitted
- 9 May 2025
- Last updated
- 29 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Because it is not planned to published in any ICMJE journal.
Study at a glance
From the registry record, last updated by the sponsor on 29 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessing Metabolic Health With Stable Isotope Tracer Techniques in Adults With Obesity
- ClinicalTrials.gov ID
- NCT07020741
- Acronym / sponsor ID
- Si-OBA / IRB25-0166
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 8 participants (estimated)
- Lead sponsor
- University of Illinois at Urbana-ChampaignUniversity, hospital or other
- Study start
- 12 Sep 2025 (actual)
- Primary completion
- 30 Aug 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 13 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In a crossover design, 8 participants will receive caloric drinks containing stable isotopes. In one arm of the study, participants will consume 6 hourly drinks containing two stable isotopes. Repeated blood, breath, urine, and muscle biopsies will be taken. In the second arm, participants will consume 1 drink containing 75g glucose, labeled with two stable isotopes of glucose. Periodic blood and breath will be taken over three hours.
Detailed description
- Enrollment, Informed Consent, and Screening Questionnaires (Virtual): Prior to study enrollment, participants will be asked to read a digital copy of an informed consent document provided using the e-Consent framework through the Research Electronic Data Capture (REDCap) system. Should participants have any questions about the study after reading the document, they will be encouraged to contact the research team prior to providing informed consent. Upon provision of informed consent, participants will receive an email with questionnaires designed to assess eligibility for the study through REDCap. Specifically, participants will be asked to complete a health and medical history questionnaire, physical activity readiness questionnaire (PARQ), International Physical Activity Questionnaire Long Form (IPAQ), and Godin-Shephard Leisure-Time Physical Activity Questionnaire (LTPAQ). Information from the medical history questionnaire, PARQ, and LTPAQ will be used to assess exclusion criteria and the IPAQ be used to assess baseline habitual activity level. Upon completion of these questionnaires, the research team will review responses and determine eligibility. Should Participants be eligible, researchers will work with the participant to schedule subsequent visits
- Preliminary Testing (Visit 1): Participants will arrive for the preliminary testing session after an overnight fast.
Urine samples: 30mL of urine at time points -30 min, 0 min, 240 min, 300 min, and 360 min. Briefly, participants will be provided with a urine collection cup, alcohol wipes, and gloves and asked to fill the cup about 3/4 of they way.
Blood Collection: ~88 mL will be collected during the trial.
Breath Collection: At -30 minutes, 0 minutes, 120 minutes, 240 minutes, 300 minutes, 360 minutes, we will measure the air exhaled. To do this, participants breathe normally through a hose. Immediately after, they will exhale into a separate mouthpiece attached to a plastic bag.
Muscle Collection: A total of 2 muscle biopsies will be collected during the trial. The biopsy procedure involves removal of a small piece of muscle tissue using a sterile hollow needle (Bergström needle) and will be performed by Dr. Nicholas Burd under the auspices of Dr. Jared Willard, MD. Participants will rest on a bed and the area for the biopsy will be shaved, if required. Subsequently, the area will be sterilized using 4% chlorhexidine gluconate before 5 mL of local anesthetic (2% Xylocaine with 1:100,000 epinephrine) is injected subcutaneously with special care to avoid infiltrating the muscle. Once the anesthetic is active, a small incision will be made in the skin in order to create an opening through which to put the biopsy needle for tissue collection. Dr. Burd will quickly cut of a small piece of muscle. the subjects may feel a sensation of deep pressure in their leg. A sterile disposable drape will be placed under the participant's thigh and sterile gloves will be used for all biopsy procedures.
After the biopsy is completed, a trained research team member will apply pressure with sterile gauze until the bleeding stops (at least 15 minutes). Subsequently, the incision site will be closed using butterfly stitches (Steri-strips) following by application of a bandage. An elastic pressure wrap will be applied on top of the bandage in order to minimize the chance of bruising. Participants will then be instructed to leave the butterfly stitches and the pressure wrap on the wound for 96 and 24 hrs, respectively.
The participant will be provided with a "biopsy care kit" (described in section 10.1/Biopsy care kit) in order to properly care for the incision after leaving the laboratory. A member of the research team will contact the participants in the day following the trial to check on the healing process.
After blood, breath, and muscle samples of time 0, participants will drink the first of a series of drinks containing [13C]phenylalanine and [2H5]phenylalanine at a ratio of 1:10 with a 1:10 ratio of total tracer to tracee (naturally occurring phenylalanine) The first drink will be primed with NaH13CO2 (0.176 mg/kg) in addition to [13C]phenylalanine and [2H5]phenylalanine mixture. Drinks will be consumed every 30 minutes for the duration of the procedure.
These drink will also contain 1.2x estimated RMR calories (divided into 12 drinks)
VCo2: Carbon dioxide production (VCO2) will be determined from expired air sampled by open circuit spirometry using an on-line, computer-based acquisition system. Participants will breathe through a one-way, high velocity non-rebreathing valve. The volume of expired air is measured by a gas flow meter. The carbon dioxide concentrations of expired air are assessed by a carbon dioxide analyser. Analog data from the gas analyser and flow meter is digitized and sent to an IBM compatible PC for calculation of VCO2 converted to Standard Temperature and Pressure Dry. Immediately after VCO2 analysis is performed (5 min), subjects are asked to exhale into a separate mouthpiece attached to a plastic bag. This particular breath sample is stored in a sterile vacutainer for future analysis of stable isotope tracer enrichment in the breath. The measurement of carbon dioxide production (VCO2) and the measurement of tracer enrichment in the breath allow us to assess how much of the protein is used for energy, rather than for building skeletal muscle proteins. Subjects are not expected to experience any discomfort from this procedure, nor will it influence their physical well-being.
(Visit 4) Stable Isotope OGTT: within 7 days after the first trail participants will be asked to return to the lab for a second procedure.
Blood Collection: Blood collection procedures will be exactly as described above. There will be a total of 9 blood collections (time -10, 10, 20, 30, 60. 90, 120, 150, 180) minutes Breath Collection: Breath collection procedures will be exactly as described above. There will be a total of 9 breath collections (-10, 10, 20, 30, 60, 90, 120, 150, 180) minutes After the blood and breath collection for time -10 minutes, participants will be asked to consume a 75 g Glucose Drink dissolved in 250 ml of water enriched with [6,6_2H2]glucose and [13C6]glucose. As stated above, blood and breath samples will be taken periodically over the next 3 hours.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- The study will employ a crossover model where they will complete 2 of 2 conditions, in a randomized order.
| Arm | Type | Receives |
|---|---|---|
| IAAO | Experimental | Procedure: Indispensable Amino Acid OxidationParticipants will ingest a series of 6 hourly beverages containing 50% of the daily intake of 1.1g/kg/day |
| SIOGTT | Experimental | Procedure: Stable Isotope Oral Glucose Tolerance TestParticipants will consume one 75g glucose drink dissolved in 250 ml of water. |
Who may qualify
- Ages
- 19 to 59 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- ages 19-59
- Obese >/= 30 kg/m^2 and >/= 102 cm for males and >/= 88 cm for females
- Godin Leisure-time or exercise questionnaire <14 units
Key exclusion criteria (7 listed)
- Pregnant or become pregnant
- Any known food allergies
- Smoker
- Are physically active
- Have any known metabolic diseases
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Indispensable Amino Acid OxidationAlso: IAAOParticipants will ingest six hourly meals designed to provide 50% of the daily intake of 1.1 g·kgLBM. Additional energy (1.5x daily resting metabolic rate), carbohydrate (55%), and fat (35%) will be provided in beverages and protein-free cookies (for palatability). The first drink will contain priming doses of NaH13CO2 (0.176 mg·kg-1), [13C]phenylalanine (1.86 mg·kg-1), [2H5]phenylalanine (0.34 mg·kg-1) with all subsequent drinks containing 1.2 mg·kg-1 [13C]phenylalanine and 0.51 mg·kg-1 [2H5]phenylalanine. | Procedure or surgery | IAAO |
| Stable Isotope Oral Glucose Tolerance TestAlso: Si OGTTParticipants will consume a 75g glucose drink dissolved in 250 ml of water enriched with [6,6_2H2]glucose and [13C6]glucose. | Procedure or surgery | SIOGTT |
Primary outcome
Define obesity-related whole body protein efficiency based of the IAAO method
Time frame: 0 - 6 hours observational period ingesting six hourly meals, within 1 week of preliminary testing. Baseline measures taken at --30 minutes.
Amino Acid Oxidation of phenylalanine will be measured using the IAAO method by periodic ingestion of amino acid mixture. Trials will start at ~7:00 am (-30 minutes) with a total duration of 6.5 hours (390 minutes) Measurements of breath (-30, 0, 120, 240, 270, 300, 330 and 360 minutes), Urine (-30, 0, 240, 300, and 360 minutes), muscle biopsy (-30 and 360 minutes) and blood (-30, 0, 30, 60, 90,120, 180, 240, 300, and 360 minutes) will be used to determine the whole body efficiency of protein in obese populations.
Assessment of oral glucose tolerance based on a dual tracer technique
Time frame: 0- 3 hour observational period. Within 1 week of the prospective arm. Baseline taken at -30 minutes.
Measure glucose kinetics via [13C] and D5 Glucose over 3 hours to determine glucose tolerance. Trials will start at ~7:00 am (-10 minutes) and last ~ 3 hours. (190 minutes)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Apr 2026.
- Individual participant dataSharing planned: No. Because it is not planned to published in any ICMJE journal.
Related trials for Obese Patients (BMI ≥ 30 kg/m²)
Recruiting
Therapeutic Potential of a Synbiotic to Improve Mental Health in Subjects With Obesity.
Obese Patients (BMI ≥ 30 kg/m²), Anxiety
Recruiting
Pistachio Snacking and Metabolic Flexibility
Overweight (BMI > 25), Obese But Otherwise Healthy Participants
Recruiting
Eatit's Obesity Intervention: Effects on Weight, Eating Habits and Health
Overweight and Obese Adults, Obese Patients (BMI ≥ 30 kg/m²)
RecruitingPhase 2
A Study to Investigate the Efficacy and Safety of Two Different Doses of Twice Daily Distal Jejunal-release Dextrose Beads Formulations Combined With a Gel Composition Compared to Placebos in Obese Subjects With Weight Related Comorbidities
Obese With Comorbidities, Obese Patients (BMI ≥ 30 kg/m²)
Active, not recruiting
Modifications to Gastric Sleeve: Implications for GRED and Quality of Life
Obese Patients (BMI ≥ 30 kg/m²), Obese Patients
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Indispensable Amino Acid Oxidation and Stable Isotope Oral Glucose Tolerance Test in people with Obese Patients (BMI ≥ 30 kg/m²) and Glucose Metabolism, run by University of Illinois at Urbana-Champaign at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 29 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Nicholas Burd (Associate Professor), PhD (2172440970, naburd@illinois.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Define obesity-related whole body protein efficiency based of the IAAO method (time frame: 0 - 6 hours observational period ingesting six hourly meals, within 1 week of preliminary testing. Baseline measures taken at --30 minutes.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2026; AzTrials last refreshed its copy on 26 Oct 2026.